Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256996 | 1.00 | HSD17B10 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL6783598 | 1.00 | HSD17B10 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL196944 | 0.86 | FKBP1A (0.45) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL14045138 | 0.86 | FKBP1A (0.45) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL16000757 | 0.85 | DPP4 (0.46) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL18065823 | 0.85 | HSD17B10 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL196943 | 0.85 | HSD17B10 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL2115151 | 0.85 | HSD17B10 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL24749796 | 0.84 | KLK5 (0.43) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 | |
| SCHEMBL6786304 | 0.84 | HSD17B10 (0.42) | HSD17B10KLK5FKBP1ASMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003051848-A2 | IMIDAZOLIDINEACETIC ACID DERIVATIVES | FERRING BV (NL) | 2003-06-26 | — | — | WO | claimed |
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-04-06 | — | — | US | disclosed |
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-04-06 | — | — | US | disclosed |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| US-20180354969-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2018-12-13 | — | — | US | disclosed |
| US-20180282333-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2018-10-04 | — | — | US | disclosed |
| EP-3380484-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| EP-3380472-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| EP-3380473-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089849-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089848-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089848-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089849-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089847-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089847-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354969-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | NR4A3, SLC39A14, SLC39A3 | HSD17B10 3030/4885KLK5 3987/4885FKBP1A 4077/4885 |
| US-20180282333-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | NR2E1, NR2E3, NR4A1 | HSD17B10 2836/4885KLK5 4743/4885FKBP1A 3809/4885 |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HSD17B10 4165/4885KLK5 3779/4885FKBP1A 4489/4885 |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | SLC39A14, SLC39A11, TMEM14C | HSD17B10 4165/4885KLK5 3779/4885FKBP1A 4489/4885 |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HSD17B10 4165/4885KLK5 3779/4885FKBP1A 4489/4885 |
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | NR2E1, NR2E3, NCOR1 | HSD17B10 3035/4885KLK5 4707/4885FKBP1A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.